Epigenetics and Transcriptomics Core

表观遗传学和转录组学核心

基本信息

  • 批准号:
    10706503
  • 负责人:
  • 金额:
    $ 33.23万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-09-20 至 2027-08-31
  • 项目状态:
    未结题

项目摘要

ABSTRACT The function of the Epigenetics and Transcriptomics Core (Core B) is to identify the key gene networks and cis-regulatory mechanisms that define the pulmonary endothelium as an innate immune ‘organ’ during lung injury and repair. Core B will provide high-throughput production and optimal mining of genome-wide gene expression and chromatin datasets, for all three projects in this Program. The Core B leader has pioneered such approaches in stem cells and is now applying these analysis platforms to lung endothelial cells in a comprehensive and integrative manner. We have optimized the methods for several next generation sequencing approaches, including low cell number RNA-seq, ChIP-seq and ATAC-seq, and can effectively collect, manage, analyze, integrate, and interpret the generated data specifically in freshly isolated endothelial cells. By combining all four technologies we will develop a multi-dimensional view of the epigenetic programming of endothelial cells (EC) and reveal their modulatory interactions with circulating immune cells. On this basis, Core B will provide a foundation for the more specific and sophisticated needs of each individual project. Indeed, each project focuses on gene regulatory networks that are among the most robustly regulated across lung injury and repair models. Through the development and use of epigenetic and transcriptomic assays coupled with next generation sequencing, Core B will assist each Project in uncovering the molecular mechanisms and develop testable hypothesis about genes associated with EC innate immunity and their role in inflammatory response. These include the exploration of the epigenetic and transcriptomic changes that occur in response to endoplasmic reticulum localized Y143phosphorylated sphingosine 1 phosphate receptor 1 (S1PR1), as EC convert from an anti-inflammatory to an immune-active lineage in Project 1; delineate the cis-regulatory mechanisms and chromatin-based pathways that control the expression of ubiquitin E3 ligase CHFR in Project 2; and examine the role of epigenetic programs in the initiation of lung endothelial cell mitophagy and mitochondrial biogenesis as well as the downstream effectors of mitophagy-induced signals in Project 3. Ultimately, Core B represents a central conduit for genomic and bioinformatic flow of data for this PPG, providing data-generation, data-storage and data-sharing functions and therefore contributing significantly to further understanding the immune regulatory function of lung endothelium.
摘要

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Konstantinos Chronis其他文献

Konstantinos Chronis的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Konstantinos Chronis', 18)}}的其他基金

Reprogramming Gene Regulatory Networks to a Hematopoietic Stem Cell State
将基因调控网络重编程为造血干细胞状态
  • 批准号:
    10716641
  • 财政年份:
    2023
  • 资助金额:
    $ 33.23万
  • 项目类别:
Epigenetics and Transcriptomics Core
表观遗传学和转录组学核心
  • 批准号:
    10494613
  • 财政年份:
    2022
  • 资助金额:
    $ 33.23万
  • 项目类别:

相似海外基金

Development of small molecule inhibitors as anti-inflammatory agents and antidotes for arsenicals
开发作为抗炎剂和砷解毒剂的小分子抑制剂
  • 批准号:
    10727507
  • 财政年份:
    2023
  • 资助金额:
    $ 33.23万
  • 项目类别:
Discovery of New Anti-Inflammatory Agents to Treat COPD
发现治疗慢性阻塞性肺病的新型抗炎药
  • 批准号:
    9194162
  • 财政年份:
    2016
  • 资助金额:
    $ 33.23万
  • 项目类别:
Synthesis of anti-inflammatory agents and their structure-activity relationships studies
抗炎药的合成及其构效关系研究
  • 批准号:
    496858-2016
  • 财政年份:
    2016
  • 资助金额:
    $ 33.23万
  • 项目类别:
    University Undergraduate Student Research Awards
NAAA Inhibitors as Anti-inflammatory Agents, Phase II
NAAA 抑制剂作为抗炎剂,II 期
  • 批准号:
    9201955
  • 财政年份:
    2015
  • 资助金额:
    $ 33.23万
  • 项目类别:
Novel flavonoids as anti-inflammatory agents in alcoholism
新型黄酮类化合物作为酒精中毒的抗炎剂
  • 批准号:
    8251289
  • 财政年份:
    2014
  • 资助金额:
    $ 33.23万
  • 项目类别:
TLR-7 Agonists as Targeted Anti-inflammatory Agents in Arthritis
TLR-7 激动剂作为关节炎的靶向抗炎药
  • 批准号:
    8302750
  • 财政年份:
    2012
  • 资助金额:
    $ 33.23万
  • 项目类别:
Design and in vivo delivery of novel anti-inflammatory agents
新型抗炎剂的设计和体内递送
  • 批准号:
    267940
  • 财政年份:
    2012
  • 资助金额:
    $ 33.23万
  • 项目类别:
    Operating Grants
Development of inlammasome inhibitors to be used as anti-inflammatory agents
开发用作抗炎剂的inlammasome抑制剂
  • 批准号:
    8403458
  • 财政年份:
    2012
  • 资助金额:
    $ 33.23万
  • 项目类别:
TLR-7 Agonists as Targeted Anti-inflammatory Agents in Arthritis
TLR-7 激动剂作为关节炎的靶向抗炎药
  • 批准号:
    8472443
  • 财政年份:
    2012
  • 资助金额:
    $ 33.23万
  • 项目类别:
Development of inlammasome inhibitors to be used as anti-inflammatory agents
开发用作抗炎剂的inlammasome抑制剂
  • 批准号:
    8549297
  • 财政年份:
    2012
  • 资助金额:
    $ 33.23万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了